Antioxidant and Vascular Effects of Gliclazide in Type 2 Diabetic Rats Fed High-Fat Diet

C. M. SENA\textsuperscript{1,2}, T. LOURO\textsuperscript{1,2}, P. MATAFOME\textsuperscript{1,2}, E. NUNES\textsuperscript{1,2}, P. MONTEIRO\textsuperscript{3}, R. SEIÇA\textsuperscript{1,2}

\textsuperscript{1}Institute of Physiology, Faculty of Medicine, University of Coimbra, \textsuperscript{2}IBILI, Faculty of Medicine, University of Coimbra, \textsuperscript{3}Basic Research Unit in Cardiology, Cardiology Department, Coimbra University Hospital and Medical School, Coimbra, Portugal

Received January 3, 2008
Accepted February 13, 2008
On-line April 1, 2008

Summary
Diabetes mellitus is characterized by oxidative stress, which in turn determines endothelial dysfunction. Gliclazide is a sulphonylurea antidiabetic drug with antioxidant effects due to its azabicyclococyl ring. It has been reported to potentially protect the vasculature through improvements in plasma lipid levels and platelet function. We hypothesized that gliclazide has a beneficial effect on endothelial function in Goto-Kakizaki rats (GK), an animal model of type 2 diabetes fed an atherogenic diet for 4 months. We evaluated the influence of gliclazide on both metabolic and oxidative status and NO-mediated vasodilation. GKAD rats showed increased oxidative stress and impaired endothelium-dependent vasodilation. GKAD rats treated with gliclazide showed increased sensitivity to NO-mediated vasodilation, a significant decrease in fasting glycemia and insulinemia, and a significant decrease in systemic oxidative stress. In conclusion, our results suggest that gliclazide treatment improves NO-mediated vasodilation in diabetic GK rats with dyslipidemia probably due to its antioxidant effects, although we cannot rule out substantial benefits due to a reduction in fasting blood glucose. The availability of a compound that simultaneously decreases hyperglycemia, hyperinsulinemia, and inhibits oxidative stress is a promising therapeutic candidate for the prevention of vascular complications of diabetes.

Key words
Endothelium • Nitric oxide • Diabetes mellitus • Gliclazide • Oxidative stress

Introduction

The increase in oxidative stress that is associated with the chronic hyperglycemia of diabetes mellitus plays a key role in the genesis of endothelial dysfunction (Giugliano et al. 1996, Pennathur and Heinecke 2004). Agents with antioxidant properties improve the function of the vessels in animal models of diabetes (Da Ros et al. 2004, Hamilton et al. 2007). We have recently reported that impaired endothelial dysfunction and increased oxidative stress was improved by α-lipoic acid, in old Goto-Kakizaki diabetic rats (Sena et al. 2008).

Gliclazide is a second-generation sulfonylurea antihyperglycemic agent (Campbell et al. 1991) that stimulates insulin secretion from pancreatic β cells by inhibiting ATP-dependent potassium channels. ATP-dependent potassium channels also mediate a variety of functions in heart and blood vessels (Nichols and Lederer 1992) Thus it is possible that sulfonylurea agents would have some effects on the vascular function aside from their effects on glycemic control. In diabetic animal models, it has also been reported that gliclazide potentially protects the vasculature through improvements in plasma lipids and platelet function (Palmer and Brogden 1993). Mechanisms may include the ability of the drug to increase tissue plasminogen activator, and its properties as a free radical scavenger. (Scott et al. 1991, Jennings et al. 1992, Desfaits et al. 1997, O’Brien et al. 2000). The aim of the present work was to address whether the gliclazide influenced endothelial dysfunction and oxidative stress in Goto-Kakizaki diabetic rats fed a high-fat diet.
Methods

Experimental animals

Wistar and Goto-Kakizaki rats were obtained from our local breeding colony (Animal Research Center Laboratory, University Hospital, Coimbra, Portugal). Animals were subjected to a constant daily cycle of 12 h light and 12 h darkness and constant temperature (22-24 °C) and humidity (50-60 %), with free access to water and to normal or high-fat diet between 2 and 6 months of age [Special diet 0125 (Modified A04 from Charles River), SAFE, France]. Rats were divided in four experimental groups accordingly [Wistar non-diabetic rats (W, n=12), GK diabetic rats fed a normal diet (GK control, n=16), GK diabetic rats fed an AD diet (GKAD, n=15), and GK rats fed an AD diet and treated with gliclazide (GKAD+G, n=14)]. Gliclazide (10 mg/kg/day) was administered in drinking water during four weeks before sacrifice. The experimental protocol was approved by the local Institutional Animal Care and Use Committee.

Determination of metabolic and oxidative stress parameters

After a 15-h fast, animals were anesthetized with ketamine/chlorpromazine. Blood was taken by heart puncture for determination of lipids, lipid peroxides, free fatty acid levels and insulin. For glucose tolerance tests, rats were fasted overnight and were given an intraperitoneal injection of glucose (1.75 g kg⁻¹ body weight) in phosphate buffered saline (PBS). Blood glucose was determined by sampling from the tail vein at 0, 30, 60, 90 and 120 min after injection by a glucose-oxidase method using a glucometer (Glucometer-Elite-

**Table 1. Influence of gliclazide on body weight, blood glucose, fasting insulin, lipids and free fatty acids (FFAs) in GKAD rats.**

<table>
<thead>
<tr>
<th></th>
<th>WISTAR</th>
<th>GK</th>
<th>GKAD</th>
<th>GKAD+G</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td>403.9 ± 6.9</td>
<td>312.7 ± 5.8***</td>
<td>387.3 ± 4.3***</td>
<td>395.3 ± 5.2***</td>
</tr>
<tr>
<td>FBG (mmol/l)</td>
<td>3.64 ± 0.11</td>
<td>5.17 ± 0.14***</td>
<td>7.78 ± 0.16***</td>
<td>5.45 ± 0.13***</td>
</tr>
<tr>
<td>BG 2 h after load (mmol/l)</td>
<td>4.65 ± 0.15</td>
<td>16.62 ± 0.4***</td>
<td>16.83 ± 0.83***</td>
<td>17.61 ± 1.57***</td>
</tr>
<tr>
<td>Insulin (pmol/l)</td>
<td>119.8 ± 30.1</td>
<td>265.9 ± 18.6***</td>
<td>189.9 ± 19.1†</td>
<td>105.0 ± 19.2***</td>
</tr>
<tr>
<td>Cholesterol (mmol/l)</td>
<td>1.82 ± 0.04</td>
<td>2.3 ± 0.05</td>
<td>2.6 ± 0.14***</td>
<td>2.4 ± 0.26***</td>
</tr>
<tr>
<td>Non-HDL cholesterol (mmol/l)</td>
<td>0.7 ± 0.04</td>
<td>0.71 ± 0.07</td>
<td>1.29 ± 0.13***</td>
<td>1.18 ± 0.05***</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.23 ± 0.09</td>
<td>1.69 ± 0.13*</td>
<td>2.52 ± 0.23***</td>
<td>2.24 ± 0.08***</td>
</tr>
<tr>
<td>FFAs (mmol/l)</td>
<td>0.71 ± 0.08</td>
<td>0.79 ± 0.04</td>
<td>1.13 ± 0.04***</td>
<td>0.66 ± 0.09***</td>
</tr>
</tbody>
</table>

Values are mean ± S.E.M. * P<0.05, *** P<0.001 vs. Wistar rats; † P<0.05, ‡‡‡ P<0.01, ‡‡‡‡ P<0.001 vs GK rats; ‡ P<0.05, ‡‡‡‡ P<0.001 vs. GKAD rats. FBG – fasting blood glucose.
induced constriction ($10^{-7}$ M). A cumulative dose-efficacy curve was determined. Regression analysis using three data points along the linear section of the concentration-response curve was applied to generate an equation from which the EC$_{50}$ values were determined (Sena et al. 2008).

Statistical analysis

All data were analyzed by standard computer programs (GraphPad Prism PC Software version 3.0, ANOVA) and are expressed as mean ± S.E.M. Significant differences were evaluated using either the $t$-test or ANOVA. $P<0.05$ was considered significant. Dose response curves were fitted by nonlinear regression with simplex algorithm. Relaxation responses were given as the percentage of phenylephrine-induced constriction. Comparisons of dose-response curves were evaluated by 2-way ANOVA for repeated measures.

Results

Blood parameters and body weight

Diabetic GK rats fed a normal chow diet were
hyperglycemic and hyperinsulinemic compared to Wistar rats. GK rats were normolipidemic and their body weight was decreased when compared with Wistar rats (Table 1).

After four months of high-fat diet feeding, GK diabetic rats showed a significant increase in body weight, fasting glycemia, total and non-HDL-cholesterol, triglycerides and FFA levels when compared with GK rats receiving a standard diet (Table 1). Treatment of the animals with gliclazide in drinking water significantly decreased fasting glycemia and insulinemia, total and non-HDL-cholesterol and FFA levels. The treatment did not modify body weight, triglyceride and glucose levels 2 h after glucose load (Table 1). Food consumption and water intake did not significantly change over the experimental period between the different groups studied (data not shown).

Oxidative stress biomarkers

Urinary levels of 8-OHdG were significantly higher in GK rats, when compared to age-matched Wistar rats (Fig. 1A), while plasma levels of protein carbonyl compounds were not statistically different between the two groups. Feeding AD diet for 4 months to GK rats significantly increased protein carbonyl compounds levels by 62 % (Figs 1A and 1B) and did not changed the levels of 8-OHdG. Supplementation with gliclazide significantly reduced these oxidative stress parameters (Figs 1A and 1B).

Discussion

Several studies have demonstrated impairment of endothelium-dependent relaxation associated with diabetes (Fortes et al. 1983, Durante et al. 1988). In GK diabetic rats, the reduction in endothelium-dependent vasodilation has been observed both in experiments with isolated aortic rings (Sena et al. 2008), and mesenteric...
Table 2. Effects of diabetes, high-fat and gliclazide treatment on maximal relaxation responses (%) and EC\textsubscript{50} values in response to acetylcholine and sodium nitroprusside of phenylephrine-precontracted rat thoracic aortic rings.

<table>
<thead>
<tr>
<th></th>
<th>Wistar</th>
<th>GK</th>
<th>GKAD</th>
<th>GKAD+G</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acetylcholine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(EC_{50})</td>
<td>6.88 ± 0.04</td>
<td>6.9 ± 0.09</td>
<td>5.02 ± 0.14*** §§§</td>
<td>6.69 ± 0.16**</td>
</tr>
<tr>
<td>Maximal relaxation (%)</td>
<td>99.1 ± 0.9</td>
<td>72.9 ± 1.7***</td>
<td>60.2 ± 2.1*** §§</td>
<td>55.4 ± 5.4*** §§§</td>
</tr>
<tr>
<td><strong>Sodium nitroprusside</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(EC_{50})</td>
<td>6.47 ± 0.04</td>
<td>6.2 ± 0.04***</td>
<td>5.6 ± 0.04*** §§§</td>
<td>6.67 ± 0.03*** §§§ ooo</td>
</tr>
<tr>
<td>Maximal relaxation (%)</td>
<td>99.3 ± 1.3</td>
<td>99.9 ± 1.3</td>
<td>99.1 ± 1.6</td>
<td>99.5 ± 1.1</td>
</tr>
</tbody>
</table>

Values are mean ± S.E.M. EC\textsubscript{50} values are presented as the negative logarithm (-\log\textsubscript{10} EC\textsubscript{50}) of concentration of the agonist. *** \(P<0.001\) vs. Wistar rats; §§ P<0.01, §§§ P<0.001 vs. GK rats; ooo P<0.001 vs. GKAD rats.

microvessels (Cheng et al. 2001), indicating that diabetic endothelial dysfunction affects both conductance and resistance vessels. In the present work, the results obtained in aortic rings showed impairment in endothelium-mediated responses over the 6-month period of the evolution of diabetes in the GK rat model. High-fat diet significantly impaired endothelial dysfunction and this was improved by treatment with gliclazide for 4 weeks.

It is widely accepted that increased oxidative stress occurs in diabetes (Baynes 1991, Ceriello et al. 1993), as documented by the presence of peroxidation products (Young et al. 1995) or enhanced generation of superoxide anions (Chang et al. 1993). Studies from several laboratories indicate that antioxidants improve NO-mediated endothelium-dependent relaxation in vessels from diabetic animals (Diederich et al. 1994, Rodríguez-Mañas et al. 1998, Sena et al. 2008). The main objective of this work was to analyze whether gliclazide ameliorated normal endothelial function in this rodent model of type 2 diabetes with dyslipidemia. Gliclazide has metabolic effects since this drug stimulates insulin secretion, while it also reduces insulin resistance. Therefore, our observed effects can be attributed to both direct vascular actions of gliclazide and improved insulin secretion/function. Oxidative stress and biochemical parameters of the diabetic rats were compared. When diabetic rats were treated with 10 mg/kg/day gliclazide, a reduction of fasting glycemia and lipid profile to control diabetic levels was observed, while there were no changes in body weight and two-hour postprandial blood glucose. Furthermore, FFAs, 8-OHdG and protein carbonyl groups were significantly reduced after treatment with gliclazide to the same levels as in non-diabetic Wistar rats.

It is interesting to note that the addition of 10 \(\mu\)M gliclazide to isolated vessels from GKAD rats caused no effect. This lack of \textit{in vitro} effect suggests that a direct and immediate free radical scavenging effect of gliclazide \textit{in vivo} (Scott et al. 1991) cannot account for the improvement in diabetic endothelial cell dysfunction. The effect of gliclazide \textit{in vivo} could be due to either a chronic increase of endothelium-derived vasodilators or a decrease of vasoconstrictors. In addition, there is a reduction in free radical generation or an increase in free radical scavenging. In diabetic patients treated with gliclazide, plasma reduced thiols were increased, lipid peroxides were decreased, and erythrocyte superoxide dismutase activity was elevated (Jennings et al. 1992). Our results are also consistent with the idea that gliclazide improves diabetic endothelial dysfunction by an antioxidant mechanism (Jennings et al. 1992, Desfaits et al. 1997, O'Brien and Luo 1997). However, we cannot rule out that the metabolic effects of gliclazide may also contribute to these observations. It is possible that the effect of gliclazide was at least partly mediated via improved insulin action as evidenced by the observed decrease in blood glucose levels and insulin resistance. In agreement with our results of improved endothelial function, Pagano et al. (1998) reported that treatment with gliclazide enhances ACh-induced relaxation in isolated aortic segments of alloxan-induced diabetic rabbits.

In addition, the improvement in endothelial function has been reported in streptozotocin-induced diabetic rats receiving gliclazide (Vallejo et al. 2000a). Others have also reported that gliclazide has antioxidant properties \textit{in vitro}, perhaps reversing the endothelial dysfunction caused by highly glycosylated oxyhemoglobin in human mesenteric microvessels.
The major limitation of this study is that gliclazide decreased fasting blood glucose thus we cannot rule out that gliclazide leads to improvement of oxidative stress and endothelial dysfunction due to the improvement in fasting glucose levels.

A main conclusion of the present study is that gliclazide ameliorates the endothelial dysfunction present in diabetic rats fed a high-fat diet. These beneficial effects on the vasculature may be related to the metabolic actions of the drug, to the improvements in plasma lipids and fasting glycemia and to its antioxidant properties.

Indeed, this work shows that gliclazide is able to reduce fasting hyperglycemia and systemic oxidative stress, thus contributing to increased sensitivity to NO-mediated vasodilation in diabetic GK rats with dyslipidemia.

**Conflict of Interest**

There is no conflict of interest.

**Acknowledgements**

We wish to thank Laboratory of Experimental research for animal care. This work was supported by grants from Faculty of Medicine of Coimbra and III.

**References**


DESFAITS AC, SERRI O, RENIER G: Gliclazide decreases cell mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL. *Metabolism* **46**: 1150-1156, 1997.


